Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
People who use Zepbound or Mounjaro, the dual-agonist medications, lose an average of about 20% of their body weight, while those who take Ozempic or Wegovy, the single-agonist drugs, lost an average of about 14% of their body weight
Around 10% to 20% of individuals report nausea
Restating this clinician-framed question underscores that the primary approach is physician-guided: begin with dietary and lifestyle measures, optimize hydration, consider short-term antiemetics under medical supervision, and escalate to urgent care when red flags appear
Therefore, the weight loss from Semaglutide GLP-1 is potentially sustainable but not inherently permanent
This leads to a scenario where new therapeutic strategies for diabetes must inevitably consider not only glycemic and weight control but also the reduction of both vascular and non-vascular complications
Nutrition, activity levels, and behavioral support play an important role in long-term success
